Press releases
17 Jul 2023
Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets
07 Feb 2023
Nodus Oncology Secures £2.4m ($2.9m) Investment
08 Sept 2022
Nodus Oncology announces acquisition of Basilea Pharmaceutica’s PARG inhibitor programme
06 Sept 2022
Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets
22 Mar 2022
Edinburgh cancer discovery accelerator Cumulus hires Chief Scientific Officer with 'invaluable' skills
22 Feb 2022
Cumulus Oncology Secures £4.1m ($5.6m) Investment Led by Eos Advisory
19 Sept 2021
Cumulus Oncology appoints Edinburgh Uni neuroscience graduate as Chief Operating Officer
22 Mar 2021
LDC and Cumulus Oncology announce collaboration
13 Jul 2020
Eos Backs Europe's First Oncology Drug Discovery Accelerator Cumulus
Get in touch
We are interested in talking with asset holders from different sectors, including Universities, Drug Discovery groups as well as Biotech and Pharma companies re-prioritising their oncology portfolio.
